{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T22:10:02Z","timestamp":1790892602051,"version":"4.1.0"},"reference-count":76,"publisher":"MDPI AG","issue":"14","license":[{"start":{"date-parts":[[2023,7,23]],"date-time":"2023-07-23T00:00:00Z","timestamp":1690070400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Lung cancer is a leading cause of morbidity and mortality in the United States and worldwide. The introduction of immune checkpoint inhibitors has led to a marked improvement in the outcomes of lung cancer patients. Despite these advances, there is a huge unmet need for therapeutic options in patients who are not candidates for targeted or immunotherapy or those who progress after first-line treatment. With its high mutational burden, lung cancer appears to be an attractive target for novel personalized treatment approaches. In this review, we provide an overview of two adoptive cell therapy approaches\u2013chimeric antigen receptors (CAR) T-cell therapy and Tumor-infiltrating lymphocytes (TILs) in lung cancer with an emphasis on current challenges and future perspectives. While both these therapies are still in the early phases of development in lung cancer and need more refinement, they harbor the potential to be effective treatment options for this group of patients with otherwise poor prognoses.<\/jats:p>","DOI":"10.3390\/cancers15143733","type":"journal-article","created":{"date-parts":[[2023,7,24]],"date-time":"2023-07-24T01:15:45Z","timestamp":1690161345000},"page":"3733","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Cellular Therapy for Lung Cancer: Focusing on Chimeric Antigen Receptor T (CAR T) Cells and Tumor-Infiltrating Lymphocyte (TIL) Therapy"],"prefix":"10.3390","volume":"15","author":[{"given":"Vatsala","family":"Katiyar","sequence":"first","affiliation":[{"name":"James Graham Brown Cancer Center, University of Louisville, Louisville, KY 40202, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Chesney","sequence":"additional","affiliation":[{"name":"James Graham Brown Cancer Center, University of Louisville, Louisville, KY 40202, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Goetz","family":"Kloecker","sequence":"additional","affiliation":[{"name":"James Graham Brown Cancer Center, University of Louisville, Louisville, KY 40202, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,7,23]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3322\/caac.21763","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J. Clin."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","article-title":"Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy","volume":"168","author":"Sharma","year":"2017","journal-title":"Cell"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"4585","DOI":"10.1158\/1078-0432.CCR-15-3101","article-title":"EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis","volume":"22","author":"Gainor","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1158\/2159-8290.CD-18-0099","article-title":"STK11\/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma","volume":"8","author":"Skoulidis","year":"2018","journal-title":"Cancer Discov."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1016\/j.jtho.2019.01.011","article-title":"Efficacy of Immune Checkpoint Inhibitors in KRAS-Mutant Non-Small Cell Lung Cancer (NSCLC)","volume":"14","author":"Jeanson","year":"2019","journal-title":"J. Thorac. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1200\/JCO.2004.08.163","article-title":"Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy","volume":"22","author":"Hanna","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S0140-6736(14)60845-X","article-title":"Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): A multicentre, double-blind, randomised phase 3 trial","volume":"384","author":"Garon","year":"2014","journal-title":"Lancet"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/s41571-021-00552-7","article-title":"Enhancing immunotherapy in cancer by targeting emerging immunomodulatory pathways","volume":"19","author":"Kraehenbuehl","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1056\/NEJMoa2109970","article-title":"Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma","volume":"386","author":"Tawbi","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1200\/JCO.22.02823","article-title":"Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I Study","volume":"41","author":"Champiat","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1007\/s00262-022-03142-3","article-title":"Adoptive cell therapies in thoracic malignancies","volume":"71","author":"Lasvergnas","year":"2022","journal-title":"Cancer Immunol. Immunother. CII"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa2116133","article-title":"Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma","volume":"386","author":"Locke","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1016\/S0140-6736(22)00662-6","article-title":"Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): Results from an interim analysis of an open-label, randomised, phase 3 trial","volume":"399","author":"Kamdar","year":"2022","journal-title":"Lancet"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/s41591-021-01622-0","article-title":"Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: The phase 2 ELARA trial","volume":"28","author":"Fowler","year":"2022","journal-title":"Nat. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa1709919","article-title":"Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia","volume":"378","author":"Park","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1200\/JCO.22.00842","article-title":"Ciltacabtagene Autoleucel, an Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed\/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up","volume":"41","author":"Martin","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"4550","DOI":"10.1158\/1078-0432.CCR-11-0116","article-title":"Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy","volume":"17","author":"Rosenberg","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/nature12213","article-title":"Mutational heterogeneity in cancer and the search for new cancer-associated genes","volume":"499","author":"Lawrence","year":"2013","journal-title":"Nature"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1158\/2159-8290.CD-12-0548","article-title":"The Basic Principles of Chimeric Antigen Receptor Design","volume":"3","author":"Sadelain","year":"2013","journal-title":"Cancer Discov."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e84","DOI":"10.1002\/acg2.84","article-title":"TRUCKS, the fourth-generation CAR T cells: Current developments and clinical translation","volume":"3","author":"Chmielewski","year":"2020","journal-title":"Adv. Cell Gene Ther."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"903562","DOI":"10.3389\/fimmu.2022.903562","article-title":"Utility and Drawbacks of Chimeric Antigen Receptor T Cell (CAR-T) Therapy in Lung Cancer","volume":"13","author":"Kandra","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1158\/2159-8290.CD-18-0442","article-title":"Tumor Antigen Escape from CAR T-cell Therapy","volume":"8","author":"Majzner","year":"2018","journal-title":"Cancer Discov."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/s41577-020-0306-5","article-title":"A guide to cancer immunotherapy: From T cell basic science to clinical practice","volume":"20","author":"Waldman","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"4272","DOI":"10.4049\/jimmunol.168.9.4272","article-title":"Cutting edge: Regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation","volume":"168","author":"Woo","year":"2002","journal-title":"J. Immunol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/mt.2010.24","article-title":"Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2","volume":"18","author":"Morgan","year":"2010","journal-title":"Mol. Ther."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"e20","DOI":"10.1200\/JCO.2006.05.9964","article-title":"Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: First clinical experience","volume":"24","author":"Lamers","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1158\/1078-0432.CCR-18-1278","article-title":"Transcriptomic and Protein Analysis of Small-cell Bladder Cancer (SCBC) Identifies Prognostic Biomarkers and DLL3 as a Relevant Therapeutic Target","volume":"25","author":"Koshkin","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1002\/JLB.5MA0122-467R","article-title":"CAR NK-92 cells targeting DLL3 kill effectively small cell lung cancer cells in vitro and in vivo","volume":"112","author":"Liu","year":"2022","journal-title":"J. Leukoc. Biol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1158\/1078-0432.CCR-22-2293","article-title":"Allogeneic CAR T Cells Targeting DLL3 Are Efficacious and Safe in Preclinical Models of Small Cell Lung Cancer","volume":"29","author":"Zhang","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy\u2014Assessment and management of toxicities","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/s41591-018-0041-7","article-title":"CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade","volume":"24","author":"Giavridis","year":"2018","journal-title":"Nat. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"224ra25","DOI":"10.1126\/scitranslmed.3008226","article-title":"Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia","volume":"6","author":"Davila","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome","volume":"124","author":"Lee","year":"2014","journal-title":"Blood"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1158\/2159-8290.CD-17-1319","article-title":"Clinical and Biological Correlates of Neurotoxicity Associated with CAR T-cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia","volume":"8","author":"Santomasso","year":"2018","journal-title":"Cancer Discov."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1158\/2159-8290.CD-17-0698","article-title":"Endothelial Activation and Blood\u2013Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells","volume":"7","author":"Gust","year":"2017","journal-title":"Cancer Discov."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1182\/blood-2015-08-665547","article-title":"Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy","volume":"127","author":"Gardner","year":"2016","journal-title":"Blood"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1158\/2159-8290.CD-15-1020","article-title":"Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy","volume":"5","author":"Sotillo","year":"2015","journal-title":"Cancer Discov."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1056\/NEJMoa1610497","article-title":"Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy","volume":"375","author":"Brown","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/nrclinonc.2017.166","article-title":"Tumour heterogeneity and resistance to cancer therapies","volume":"15","author":"Shaw","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"4414","DOI":"10.1158\/0008-5472.CAN-20-0069","article-title":"Spatial Density and Distribution of Tumor-Associated Macrophages Predict Survival in Non-Small Cell Lung Carcinoma","volume":"80","author":"Zheng","year":"2020","journal-title":"Cancer Res."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/978-3-319-24932-2_5","article-title":"The Microenvironment of Lung Cancer and Therapeutic Implications","volume":"890","author":"Mittal","year":"2016","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1172\/JCI45817","article-title":"Matrix architecture defines the preferential localization and migration of T cells into the stroma of human lung tumors","volume":"122","author":"Salmon","year":"2012","journal-title":"J. Clin. Investig."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1038\/s41586-019-0985-x","article-title":"NR4A transcription factors limit CAR T cell function in solid tumours","volume":"567","author":"Chen","year":"2019","journal-title":"Nature"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1016\/j.cell.2018.03.038","article-title":"Universal Chimeric Antigen Receptors for Multiplexed and Logical Control of T Cell Responses","volume":"173","author":"Cho","year":"2018","journal-title":"Cell"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"9577","DOI":"10.1021\/acs.jmedchem.0c02054","article-title":"Optimization of CAR-T Cell-Based Therapies Using Small-Molecule-Based Safety Switches","volume":"64","author":"Zheng","year":"2021","journal-title":"J. Med. Chem."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1021\/acssynbio.1c00007","article-title":"Switchable CAR-T Cells Outperformed Traditional Antibody-Redirected Therapeutics Targeting Breast Cancers","volume":"10","author":"Cao","year":"2021","journal-title":"ACS Synth. Biol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"759","DOI":"10.4049\/jimmunol.1401710","article-title":"Coexpressed Catalase Protects Chimeric Antigen Receptor-Redirected T Cells as well as Bystander Cells from Oxidative Stress-Induced Loss of Antitumor Activity","volume":"196","author":"Ligtenberg","year":"2016","journal-title":"J. Immunol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.ccell.2019.09.006","article-title":"Combination Immunotherapy with CAR T Cells and Checkpoint Blockade for the Treatment of Solid Tumors","volume":"36","author":"Grosser","year":"2019","journal-title":"Cancer Cell"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1038\/nature07205","article-title":"Cancer-related inflammation","volume":"454","author":"Mantovani","year":"2008","journal-title":"Nature"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1018962","DOI":"10.3389\/fimmu.2022.1018962","article-title":"Tumor-infiltrating lymphocytes for treatment of solid tumors: It takes two to tango?","volume":"13","author":"Kazemi","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1038\/s41591-021-01462-y","article-title":"Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: A phase 1 trial","volume":"27","author":"Creelan","year":"2021","journal-title":"Nat. Med."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1056\/NEJM198812223192527","article-title":"Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report","volume":"319","author":"Rosenberg","year":"1988","journal-title":"N. Engl. J. Med."},{"key":"ref_57","first-page":"1934","article-title":"Use of adoptive transfer of tumor-infiltrating lymphocytes alone or in combination with cisplatin-containing chemotherapy in patients with epithelial ovarian cancer","volume":"51","author":"Aoki","year":"1991","journal-title":"Cancer Res."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1007\/BF00199837","article-title":"Tumor-derived interleukin-2-dependent lymphocytes in adoptive immunotherapy of lung cancer","volume":"24","author":"Kradin","year":"1987","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1200\/JCO.2014.58.9093","article-title":"Complete regression of metastatic cervical cancer after treatment with human papillomavirus-targeted tumor-infiltrating T cells","volume":"33","author":"Draper","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1038\/s41591-018-0040-8","article-title":"Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer","volume":"24","author":"Zacharakis","year":"2018","journal-title":"Nat. Med."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"100124","DOI":"10.1016\/j.esmoop.2021.100124","article-title":"The prognostic impact of tumor mutational burden (TMB) in the first-line management of advanced non-oncogene addicted non-small-cell lung cancer (NSCLC): A systematic review and meta-analysis of randomized controlled trials","volume":"6","author":"Galvano","year":"2021","journal-title":"ESMO Open"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.ccell.2018.03.018","article-title":"Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer","volume":"33","author":"Hellmann","year":"2018","journal-title":"Cancer Cell"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/S0140-6736(89)91609-7","article-title":"Tumour-infiltrating lymphocytes and interleukin-2 in treatment of advanced cancer","volume":"1","author":"Kradin","year":"1989","journal-title":"Lancet"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1002\/(SICI)1097-0142(19960715)78:2<244::AID-CNCR9>3.0.CO;2-L","article-title":"A randomized trial of adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 versus standard therapy in the postoperative treatment of resected nonsmall cell lung carcinoma","volume":"78","author":"Ratto","year":"1996","journal-title":"Cancer"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1159\/000438523","article-title":"Prognostic Role of Tumor-Infiltrating Lymphocytes in Lung Cancer: A Meta-Analysis","volume":"37","author":"Geng","year":"2015","journal-title":"Cell Physiol. Biochem."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/sj.bjc.6602934","article-title":"Concurrent infiltration by CD8+ T cells and CD4+ T cells is a favourable prognostic factor in non-small-cell lung carcinoma","volume":"94","author":"Hiraoka","year":"2006","journal-title":"Br. J. Cancer"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.lungcan.2012.04.011","article-title":"Increase of regulatory T cells in metastatic stage and CTLA-4 over expression in lymphocytes of patients with non-small cell lung cancer (NSCLC)","volume":"77","author":"Erfani","year":"2012","journal-title":"Lung Cancer"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1097\/JTO.0b013e31820b80ca","article-title":"Foxp3(+) regulatory T cells and natural killer cells distinctly infiltrate primary tumors and draining lymph nodes in pulmonary adenocarcinoma","volume":"6","author":"Schneider","year":"2011","journal-title":"J. Thorac. Oncol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1007\/s00262-018-2174-4","article-title":"Establishment of adoptive cell therapy with tumor infiltrating lymphocytes for non-small cell lung cancer patients","volume":"67","author":"Farhi","year":"2018","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"A1","DOI":"10.1136\/jitc-2021-SITC2021.458","article-title":"458 First phase 2 results of autologous tumor-infiltrating lymphocyte (TIL; LN-145) monotherapy in patients with advanced, immune checkpoint inhibitor-treated, non-small cell lung cancer (NSCLC)","volume":"9","author":"Schoenfeld","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Zhao, Y., Deng, J., Rao, S., Guo, S., Shen, J., Du, F., Wu, X., Chen, Y., Li, M., and Chen, M. (2022). Tumor Infiltrating Lymphocyte (TIL) Therapy for Solid Tumor Treatment: Progressions and Challenges. Cancers, 14.","DOI":"10.3390\/cancers14174160"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.omto.2022.01.004","article-title":"Highly efficient PD-1-targeted CRISPR-Cas9 for tumor-infiltrating lymphocyte-based adoptive T cell therapy","volume":"24","author":"Chamberlain","year":"2022","journal-title":"Mol. Ther. Oncolytics"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"S952","DOI":"10.1016\/j.annonc.2022.07.1009","article-title":"883TiP A phase I\/II open-label study (IOV-GM1-201) of TALEN-mediated PD-1 inactivated autologous tumor-infiltrating lymphocytes (TIL; IOV-4001) in patients with advanced melanoma and NSCLC","volume":"33","author":"Chesney","year":"2022","journal-title":"Ann. Oncol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1089\/hum.2007.0171","article-title":"Adoptive cell therapy for patients with melanoma, using tumor-infiltrating lymphocytes genetically engineered to secrete interleukin-2","volume":"19","author":"Heemskerk","year":"2008","journal-title":"Hum. Gene Ther."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"5458","DOI":"10.1158\/1078-0432.CCR-10-0712","article-title":"Transduction of tumor-specific T cells with CXCR2 chemokine receptor improves migration to tumor and antitumor immune responses","volume":"16","author":"Peng","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1038\/gt.2012.75","article-title":"Inhibition of TGF-\u03b2 signaling in genetically engineered tumor antigen-reactive T cells significantly enhances tumor treatment efficacy","volume":"20","author":"Zhang","year":"2013","journal-title":"Gene Ther."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/14\/3733\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:17:22Z","timestamp":1760127442000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/14\/3733"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,23]]},"references-count":76,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2023,7]]}},"alternative-id":["cancers15143733"],"URL":"https:\/\/doi.org\/10.3390\/cancers15143733","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,23]]}}}